Every 10-Q that Ashland (ASH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ASH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ASH filings page.
Ashland Inc. reported for the quarter ended June 30, 2026 sales of $497 million, up from $463 million a year earlier. Gross profit rose to $170 million from $132 million. Operating income was $43 million versus a prior-year operating loss of $708 million, which had included $706 million of goodwill impairment. Income from continuing operations was $41 million compared with a loss of $719 million, and after a $25 million loss from discontinued operations, net income was $16 million, or $0.35 per diluted share, versus a net loss of $742 million, or $(16.21) per share.
For the nine months ended June 30, 2026, sales were $1.365 billion versus $1.347 billion in 2025. Net income was $20 million (earnings of $0.43 per share) compared with a loss of $877 million (loss of $18.85 per share). Cash flows from continuing operations provided $295 million, up from $94 million, helping increase cash and cash equivalents to $440 million at June 30, 2026 from $215 million at September 30, 2025. Long-term debt was $1.374 billion, and the consolidated net leverage ratio was 2.3 under a new $500 million five-year revolving credit facility, with $496 million of capacity available.
Legacy and restructuring items remain significant. Discontinued operations reflected asbestos-related and other legacy losses of $25 million in the quarter. Ashland increased asbestos litigation reserves to $262 million for Ashland and $183 million for Hercules, partly offset by insurance receivables of $103 million and $53 million, respectively. Restructuring-related severance expense was $4 million for the nine months, and accelerated depreciation for plant optimization was $4 million, both below prior-year levels, while no new goodwill impairments were recorded.
Ashland Inc. reported steadier results for the quarter ended March 31, 2026, with sales of $482 million, slightly above $479 million a year earlier. Gross profit held at $147 million, but operating income declined to $39 million from $51 million as higher net interest and other costs weighed on earnings.
Net income from continuing operations was $15 million, down from $30 million, while diluted EPS from continuing operations fell to $0.32 from $0.63. For the first six months, Ashland generated $868 million in sales versus $884 million last year but swung to a small net profit of $4 million from a prior loss driven by earlier divestiture charges.
Cash generation improved meaningfully: operating activities from continuing operations provided $175 million in the first half, compared with a $21 million use last year, helping lift cash and equivalents to $343 million and keeping long‑term debt roughly flat at $1.37 billion. The balance sheet also reflects sizable long‑term asbestos and environmental reserves, though these declined modestly versus September 2025.
Ashland Inc. reported a small net loss of $12 million for the quarter ended December 31, 2025, a sharp improvement from a $165 million loss a year earlier, when results were hit by a large divestiture impairment. Quarterly sales were $386 million, down from $405 million, with modest declines across most segments.
Operating loss narrowed to $6 million from $179 million, while diluted loss per share improved to $(0.26) from $(3.50). Cash flow from continuing operations strengthened to $125 million versus a $30 million outflow, lifting cash and equivalents to $304 million. Long-term debt stood at $1.387 billion, and the company continued restructuring and manufacturing optimization efforts, incurring related costs but realizing initial savings.